acterial carriers for the mucosal delivery of antigens, particularly those capable of colonizing or invading through the mucosal epithelia, have been intensively investigated (1). Live bacterial vectors can be generated with attenuated pathogens, such as Salmonella and Listeria, or nonpathogenic commensal species, such as Lactococcus and Lactobacillus. Bacteria in the former group of are capable of inducing strong and long-lasting immune responses to passenger antigens but present serious safety concerns, whereas bacteria in the latter group are safer but typically induce much lower immune responses to the passenger antigens (1-3). As a safe nonpathogenic live bacterial vector, Bacillus subtilis, a spore-forming soil Gram-positive bacterial species, has been engineered to express antigens as either vegetative cells or spores (4, 5). As antigen carriers, B. subtilis spores have several attractive features, including a safe record of human and animal use as both probiotic and food additives, remarkable heat resistance, and rather easy genetic and bacteriological manipulation.
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Currently, two major genetic approaches have been proposed to generate recombinant B. subtilis spores as vaccine delivery vectors. The first approach relies on the expression of a heterologous protein genetically fused to surface-exposed spore coat proteins, such as CotB, CotC, or CotG (6, 7) . Such a strategy would allow a better presentation of the passenger antigen to the mucosa-associated lymphoid tissue (MALT) afferent sites, leading to the induction of adaptive immune responses, such as mucosal secretory (IgA) or systemic (IgG) antigen-specific antibody responses (6) (7) (8) . The second approach is based on a distinct rationale and has employed episomal vectors in which the target antigen is expressed under the control of a promoter (PgsiB) active only at the vegetative cell stage, which means immediately after spore germination (9) (10) (11) . This antigen delivery approach relies on the fact that B. subtilis spores germinate during transit through the gastrointestinal tract and produce the target antigen at the intestinal lumen or inside the phagocytes of antigen-presenting cells (APCs), leading to the induction of antibody responses in the serum (IgG) and mucosa (fecal IgA) (9) (10) (11) .
However, in both cases, the administration of recombinant spores via mucosal routes typically confers immune responses to the passenger antigen lower than those achieved with delivery systems based on attenuated bacterial strains capable of colonizing the mammalian gastrointestinal tract. The reduced mucosal adjuvant effects of B. subtilis spores have been attributed to several factors, such as a previously established immunity generated by the frequent ingestion of spores, the reduced amount of expressed antigens, and the rapid transit through the gastrointestinal tract, which reduces the chances of a productive interaction with the gut-associated lymphoid tissue (GALT), such as M cells and APCs at Peyer's patches (PPs) (12, 13) .
In an attempt to improve the performance of B. subtilis cells as antigen delivery vectors following mucosal spore administration, we combined the two different protein expression approaches. First, spores were engineered to express bacterial adhesins at the spore surface by genetic fusion with CotB, a B. subtilis spore coat protein. Two previously known bacterial adhesins known to promote the colonization of the mammalian gastrointestinal tract were employed: the S-layer protein (SlpA) from Lactobacillus brevis and invasin (InvA) expressed by Yersinia pseudotuberculosis (14, 15) . In a second step, the spores were genetically modified to express at the cell stage a protein fragment (the P1 protein fragment from amino acids 39 to 512 [P1 ]) derived from the P1 antigen (also known as antigen I/II, Pac, or antigen B) and originally expressed by Streptococcus mutans, the causative agent of dental caries, but also found on the surface of different pathogenic streptococci (16) (17) (18) . Notably, the S. mutans P1 protein represents the major antigen target for most anticaries vaccine approaches previously reported (19) .
Our findings demonstrate that engineered B. subtilis spores expressing bacterial adhesins persisted longer in the mouse gastrointestinal tract, particularly at Peyer's patches, and enhanced the antibody responses to the passenger antigen following delivery via the oral, nasal, and sublingual routes. Altogether, the reported strategy represents a new antigen delivery platform based on B. subtilis spores.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. Escherichia coli DH5␣ and B. subtilis 1012 (20) strains were routinely cultivated aerobically in Luria-Bertani (LB) broth (37°C). S. mutans strain NG8 (kindly provided by L. Jeannine Brady, University of Florida) was cultivated in Todd-Hewitt broth and yeast extract (0.3%) (THY) at 37°C in 5% CO 2 . Antibiotics were added to the growth media according to the strain and plasmid used. Competent E. coli and B. subtilis cells were used following established procedures (21, 22) .
Construction of the recombinant B. subtilis strains. The genes encoding the full-length Y. pseudotuberculosis InvA, which interacts with the ␤1 integrin receptor and promotes the invasion of gut epithelial cells (23) (24) (25) , and the L. brevis S-layer protein (SlpA), directly involved in the binding to fibronectin and conferring the capability to colonize the mammalian gut (26, 27) , were fused to the gene encoding the N-terminal portion of the CotB protein (275 amino acids), which has previously been employed to expose different heterologous proteins at the spore surface (6) . The sequence encoding the cotB promoter and part of the N-terminal region was amplified using the primers CotB5 (5=-GGCCATGGATCCA CGGATTAGGCCGTTTGTCC-3=; the BamHI site is underlined) and CotB3 (5=-GGCCATAAGCTTGGATGATTGATCATCTGAAGATT-3=; the HindIII site is underlined). The amplified PCR product (831 bp) was inserted into the pDG1731 vector (28) , which had previously been cleaved with BamHI and HindIII, giving rise to the pDGcotB vector. Next, the slpA and invA genes were amplified from the genomic DNA of L. brevis using the primers SlpAFw (5=-CAACGACTGCTAAGCTTATGAAGTCA TACGCT-3=; the HindIII site is underlined) and SlpARv (5=-GGCCATG AATTCCGTTATCGTTGGTGGC-3=; the EcoRI site is underlined) and from the genomic DNA of Y. pseudotuberculosis using the primers InvAFw and InvA3 (5=-GGCCATGAATTCTATTGACAGCGCACAGAGCG-3=; the EcoRI site is underlined), respectively. The amplified PCR products (662 bp for slpA and 2.9 kb for invA) were digested with the restriction enzymes HindIII and EcoRI and cloned into pDGcotB, which had previously been digested, resulting in two integrative vectors, pLDV703 (SlpA) and pLDV704 (InvA) (Fig. 1a) . All cloned sequences were confirmed by DNA sequencing. The integrative vectors were integrated at the nonessential thrC gene of the B. subtilis 1012 genome, resulting in strains LDV703* and LDV704* (Fig. 1a) . The vaccine vector pLDV702 was constructed after cloning the spaP1N gene (1.4 kb), which encodes the P1 antigen from S. mutans strain UA159 (29) , into the pHCMC03 vector under the control of PgsiB, which is active only during the vegetative growth stage (9, 30) (Fig. 1b) . Finally, pLDV702 was introduced into B. subtilis strains 1012, LDV703*, and LDV704*, originating strains LDV702 (control), LDV703, and LDV704, respectively (Fig. 1a) . Preparation of B. subtilis spores. B. subtilis spores were recovered from cultures prepared in Foerster broth (31) supplemented with chloramphenicol (30 g/ml) and incubated with aeration (200 rpm) at 37°C for 10 days. After cultivation, the spores were centrifuged and washed 3 times with sterile distilled water. The concentrations of the viable spores and vegetative cells were determined after plating serial dilutions of heat-treated samples (60 min at 65°C) on LB-chloramphenicol plates. Under the tested conditions, no contamination with vegetative cells was observed.
Extraction of spore coat proteins. The B. subtilis spore coat proteins were extracted as previously described (32) . Briefly, spores were incubated in 50 mM dithiothreitol (DTT) and 1% sodium dodecyl sulfate (SDS) at 70°C for 30 min and then harvested at 8,000 ϫ g for 10 min. Spore coat supernatant was used in enzyme-linked immunosorbent assays (ELISAs) and Western blotting assays, and both were performed with anti-SlpA or anti-InvA mouse polyclonal antibodies (kindly provided by Vasco Azevedo, Federal University of Minas Gerais, Brazil).
SDS-PAGE and Western blotting. Electrophoresis in denaturing gels was performed following a previously described protocol (33) and using a Mini-Protean II vertical electrophoresis unit (Bio-Rad). The Western blot assays were performed using previously described protocols (29) . Reactive bands were detected with a chemiluminescence kit (SuperSignal; Pierce), as previously described (29) .
Immunofluorescence of recombinant spores. Spores were fixed on glass slides using a previously described protocol (8) . Briefly, the spores were suspended in GTE-lysozyme buffer (50 mM glucose, 20 mM TrisHCl, pH 7.5, 10 mM EDTA, 2 mg/ml of lysozyme) and applied to glass slides previously treated with 0.01% poly-L-lysine (Sigma). After 5 min, excess liquid was removed. The slides were air dried, washed once with 1ϫ phosphate-buffered saline (PBS), and blocked for 30 min with 1ϫ PBS containing 2% bovine serum albumin (BSA). The spore samples were incubated for 1 h with specific anti-SlpA, anti-InvA polyclonal or preimmune sera, washed 3 times with PBS, and incubated with secondary antibody (fluorescein isothiocyanate-conjugated goat anti-mouse IgG; Invitrogen, Carlsbad, CA) for 1 h. The stained cells were viewed using a Nikon TE300 inverted epifluorescence microscope (495-nm excitation, 525-nm emission).
Quantification of P1 39-512 by recombinant B. subtilis strains. P1 expression by the B. subtilis vaccine strains was monitored in vitro after induction by high-temperature incubation (42°C for 4 h), as previously described (30) . Briefly, cells cultivated in LB broth at 37°C were shifted to 42°C at an optical density at 600 nm (OD 600 ) of 0.6 to 0.8 and incubated for an additional 4 h. The cells were collected and suspended in lysis buffer (30% sucrose, 100 mM Tris HCl, pH 7.2, 800 g/ml of lysozyme) for 30 min at 37°C, with SDS (final concentration, 1%) added to lyse the cells. The expressed P1 39-512 protein was measured by Western blotting and dot blotting using whole-cell lysates of different numbers of cells (10 2 to 10 7 CFU). Purified P1 was obtained as previously described (29) and used as a reference (3.2 to 250 ng of protein) for the quantification of the protein content in different B. subtilis strains. Reactive bands were analyzed using ImageJ software following the manufacturer's instructions.
Spore adhesion to Caco-2 cells. Adhesion of recombinant B. subtilis spores to gut epithelial cells was performed using the human Caco-2 colon carcinoma cell line (ATCC HTB37) according to a previously described procedure (34) . The Caco-2 cells were cultured in RPMI medium supplemented with 2 mM L-glutathione and 20% fetal bovine serum. Spores (5 ϫ 10 9 spores/well) were added to 24-well plates (Nunc, Thermo Scientific) containing Caco-2 cells at a concentration of 2 ϫ 10 5 cells/well. The assay was performed with medium containing gentamicin (20 g/ml) to inactivate germinated spores. Assays were performed after 2 h of incubation. The cells were lysed and heated at 65°C for 60 min, diluted in PBS, and, finally, plated on LB plates supplemented with chloramphenicol (30 g/ml).
Transit of B. subtilis spores through the mouse intestinal tract. Groups of five BALB/c mice were inoculated with a single oral dose of 10 11 spores of the tested B. subtilis strain. The mice were maintained in cages for 9 days. On each day, the fecal pellets were collected, weighed, and diluted in 5 ml of 1ϫ PBS. The samples were centrifuged at 8,000 ϫ g for 15 min (4°C), and the supernatants were serially diluted with PBS and plated before and after incubation for 60 min at 65°C on LB plates supplemented with spectinomycin (100 g/ml) and chloramphenicol (30 g/ml). The number of viable bacterial spores and vegetative cells per gram of feces was determined using the following formula: [(number of CFU/ml) ϫ 5]/weight of feces collected.
Adhesion of B. subtilis spores to murine PPs. Groups of four BALB/c mice were inoculated with a single oral dose of 5 ϫ 10 9 spores. After 1 or 6 days, the animals were sacrificed and the small intestine was aseptically removed. Fragments of the intestine were removed and washed gently with sterile saline, and the PPs were removed. The collected PPs were washed and treated with 0.2% Triton X-100 in saline. The whole-cell lysates were plated on LB plates containing spectinomycin (100 g/ml) and chloramphenicol (30 g/ml) before and after heat inactivation treatment for the determination of viable vegetative cells and spores. For histopathology analyses, PPs were aseptically removed, fixed with formalin (10%) for 24 h, placed in and processed in paraffin, and stained with hematoxylin-eosin. 8 spores in a 10-l volume, which was deposited under the tongue with the aid of a micropipette tip. For the nasal immunizations, the BALB/c mice (n ϭ 5) received a dose of 10 8 spores in a 10-l volume in the nares. Serum samples and saliva were collected 1 day before the first dose (preimmune samples), 1 day before each new set of doses, and 2 weeks after the last dose. Saliva was collected after the intraperitoneal (i.p.) injection of 0.5 ml of 0.2% pilocarpine to stimulate saliva flow. Phenylmethylsulfonyl fluoride (PMSF; 1 mM) was added to the samples to inhibit the action of proteases (35) . All samples were stored at Ϫ80°C.
ELISA. The quantifications of the antigen-specific antibody levels in the serum and saliva samples collected from the immunized mice were performed by ELISA in 96-well MaxiSorp (Nunc) plates coated with the recombinant P1 39-512 protein according to previously described procedures (29) . The absorbance values of the preimmune serum pools were used as blanks. Dilution curves were drawn for each sample, and the concentrations of antigen-specific antibodies were determined using standard curves prepared with known amounts of mouse IgG and IgA (Southern Biotech). All samples were assayed in duplicate.
Inhibition of S. mutans SAG-mediated adherence. Saliva-binding assays with the S. mutans NG8 strain were performed with purified salivary agglutinin (SAG), as described previously (36) . The percentage of S. mutans adherence or adherence inhibition to immobilized SAG was determined as previously described (29) . Briefly, purified SAG diluted in 1 volume of KPBS (2.7 mM KCl, 1.5 mM KH 2 PO 4 , 137 mM NaCl, 6.5 mM Na 2 HPO 4 , pH 7.2) was adsorbed onto the wells (100 l/well) of an Immobilon (Nunc) microtiter plate (4°C) for 16 h. The wells were washed once with TBSC (10 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl 2 , pH 7.6), blocked with 1% BSA for 1 h at 25°C, and washed once again with TBSC. Aliquots (100 l) of bacterial suspensions (prepared at an OD 600 of 1 in TBSC) were added to the wells, and the plates were incubated for 2 h at 37°C. The wells were washed twice with TBSC, and the adherent bacteria were fixed with 25% formaldehyde for 30 min at 25°C. The wells were washed twice with TBSC and stained with 0.5% crystal violet at 25°C for 1 min. Finally, the wells were washed, the dye was dissolved in 7% acetic acid, and the absorbance at 600 nm was measured. For adherence inhibition assays, the serum samples were mixed with the pretreated bacterial suspension and incubated for 30 min at 37°C, prior to the addition to the plate wells. The inhibition of S. mutans adhesion in the presence of immune serum was calculated as follows: 100 Ϫ [(A 600 of NG8 cells incubated with the tested serum sample ϫ 100)/A 600 of NG8 cells not incubated with mouse serum]. Nonimmune serum and serum from mice immunized with the spores of B. subtilis strain 1012 were used as negative controls. All tested serum samples were collected after the complete immunization regimens and diluted to a final concentration of 2 g/ml. All tests were performed in triplicate and independently repeated at least three times.
Statistical analyses. The results were analyzed using GraphPad Prism (version 5) software and are expressed as the mean Ϯ standard deviation (SD). Statistically significant differences for the Caco-2 cell adhesion test were determined using Student's t test, whereas the other statistical analyses were performed with two-way analysis of variance followed by Bonferroni posttests.
RESULTS
Construction of recombinant B. subtilis spores capable of binding mammalian gut epithelial cells. The first step in the construction of the recombinant B. subtilis strains was the generation of recombinant B. subtilis spores expressing bacterial adhesins known to bind receptors found at gut epithelial cells at the spore surface. For that purpose, the N-terminal region of CotB, a surface-exposed spore protein (6), was genetically fused with two different adhesins with receptors at gut epithelial cells: the S-layer protein (SlpA) from L. brevis, which binds to fibronectin, and the invasin protein (InvA) from Y. pseudotuberculosis, which binds to integrin. These adhesins have been demonstrated to be functional when expressed in heterologous bacterial hosts (26, 27, 37, 38, 44) . The integrative vectors, named pLDV703 (encoding the cotB::slpA fusion) and pLDV704 (encoding the cotB::invA fusion), were introduced by transformation into B. subtilis strain 1012, and stable recombinants were selected for the integration of the recombinant gene cassettes at the thrC locus, as previously described (28) (Fig.  1a) . The spore surface display of SlpA (LDV703* strain) and InvA (LDV704* strain) was confirmed by Western blotting using spore coat protein extract preparations (Fig. 1c) . Protein bands with apparent molecular masses of 54 kDa (corresponding to the molecular mass of the chimeric CotB-SlpA protein) and 137 kDa (corresponding to the molecular mass of the chimeric CotB-InvA protein) were detected in LDV703* and LDV704* spores, respectively (Fig. 1c) . To confirm the spore surface localization of the bacterial adhesins, we performed immunofluorescence analyses with anti-SlpA and anti-InvA antibodies. A shown in Fig. 1d , we observed that the anti-SlpA and anti-InvA antibodies reacted specifically with the recombinant B. subtilis spores, confirming the display of the adhesins at the spore surface. No specific reaction was detected with preimmune sera. Similarly, no reaction was detected with the anti-SlpA and anti-InvA serum samples or with vegetative cells of the parenteral LDV702 strains (data not shown and Fig. 1d) .
The second step in the construction of the recombinant B. subtilis strains involved the introduction of the gene encoding the target antigen, an N-terminal fragment of the S. mutans P1 protein (P1 ), under the control of a stress-inducible promoter (PgsiB) active only after spore germination (Fig. 1b) (9, 10) . The pLDV702 plasmid carrying the spaP1N gene was introduced into B. subtilis LDV703* and LDV704*, giving rise to the vaccine strains LDV703 and LDV704, respectively (Fig. 1a) . The expression of P1 was monitored in whole-cell extracts of vegetative cells after a temperature shift (from 37°C to 42°C). All recombinant B. subtilis strains, including the control LDV702 strain, which did not express any surface-exposed spore adhesin, expressed the target antigen, as confirmed by Western blotting with P1-specific sera (Fig. 1e) . The estimated amounts of P1 produced by the recombinant strains were 56.7 g for LDV702 and LDV703 and 5.6 g for LDV704 in a total amount of cells corresponding to 10 8 CFU (Fig. 1f) . Expression of SlpA and InvA delays transit through the mouse intestinal tract and enhances the interaction of spores with Peyer's patches. To determine whether the SlpA and InvA adhesins expressed on the spore surface would retain biological activity and affect spore behavior, we incubated B. subtilis spores with human intestinal cells (of the Caco-2 human cell lineage). The results demonstrated that spores expressing SlpA and InvA interact in vitro with intestinal cells more efficiently than spores of the control LDV702 strain do (Fig. 2a) . In addition, LDV703 and LDV704 spores persisted longer in the mouse intestinal tract, as demonstrated in BALB/c mice (Fig. 2b) . LDV702 spores were detected in feces up to 72 h after ingestion, whereas spores of the recombinant LDV703 and LDV704 strains were excreted at high numbers (Ͼ10 3 spores/g feces) up to 8 days after administration (Fig. 2b) . Taking into account the total number of spores and vegetative cells sampled from feces, mice orally dosed with spores of the LDV703 and LDV704 strains excreted 1,000-fold more bacteria and spores than mice dosed with spores of the LDV702 strain (Table 1 ). In addition, the proportion of spores in relation to the proportion of vegetative cells recovered in feces was higher in those animals ingesting spores of the LDV703 or LDV704 strain (spore/cell ratios, 2.2 and 4.7, respectively) than in mice dosed with spores of the control LDV702 strain (spore/cell ratio, 8.5) ( Table 1 ). These results indicate that the expression of SlpA or InvA increased the transit of B. subtilis spores through the mouse intestinal tract, allowing the spores to experience more germination/sporulation cycles.
In the next step, we determined if the adhesive spores would in- teract more efficiently with afferent sites of the murine GALT. For that purpose, we determined the number of B. subtilis spores detected in the PPs of mice orally dosed with spores. As indicated in Fig. 2c, 1 day after the spore administration, both the spores and cells of the three B. subtilis strains were detected in the PPs at similar numbers. Nonetheless, at 6 days after spore administration, only mice dosed with spores of the LDV703 or LDV704 strain contained viable spores in the PPs (Fig. 2d) . No differences in the size or rough histological aspects were observed in the PPs of mice treated with spores of the LDV703 or LDV704 strain compared with mice treated with spores of the control LDV702 strain (data not shown). Altogether, these results indicate that the presence of bacterial adhesins at the spore coat enhanced the interaction of B. subtilis spores with the GALT afferent sites without inducing a measurable inflammatory response.
Oral administration of the adhesive spores improves antibody responses induced to a passenger vaccine antigen. To evaluate the impact of SlpA and InvA expression on the immunogenicity of an antigen carried by B. subtilis spores after mucosal administration, BALB/c mice were immunized via the oral route with recombinant spores capable of carrying the S. mutans P1 39-512 protein after spore germination. After the administration of one dose, only mice immunized with spores of the LDV703 or LDV704 strain developed measurable anti-P1 39-512 serum IgG responses (Fig. 3a) . After a second dose, antigen-specific antibody responses were detected in mice immunized with spores of the three strains; however, animals immunized with adhesive spores developed statistically significantly higher responses than animals immunized with spores of the control strain (Fig. 3a) . After the third dose, no significant differences in the anti-P1 serum IgG responses elicited in mice immunized with the spores of the three tested B. subtilis strains were detected. A noteworthy finding was that only mice orally dosed with spores of the LDV703 or LDV704 strain developed antigen-specific IgA responses in saliva after the third dose (Fig. 3b) .
Because the P1 protein plays a pivotal role in the saliva-mediated agglutinin (SAG) adhesion of S. mutans to the tooth surface (17, 36) , we determined if antibodies raised in mice immunized with the different B. subtilis vaccine strains would block the adhesion of S. mutans to human saliva immobilized on an abiotic surface. As demonstrated in Fig. 3c , serum samples collected from mice immunized with spores of the LDV703 or LDV704 strain blocked the adhesion of S. mutans to immobilized SAG by approximately 31% and 34%, respectively (Fig. 3c) . In contrast, sera from mice immunized with LDV702 spores reduced the binding of S. mutans by only 18% (Fig. 3c) . These results indicate that the expression of SlpA or InvA by B. subtilis spores increased the immunogenicity of P1 and improved the functionality of P1-specific antibodies, allowing a more efficient blockage of bacterial adhesion.
Enhanced immunogenicity of P1 39-512 after sublingual and nasal delivery of adhesive B. subtilis spores. We also tested whether the delivery/adjuvant effects of the B. subtilis spores could also be observed after the administration of spores via different mucosal routes. For this purpose, we evaluated immunization by the sublingual and nasal routes, previously shown to promote the induction of systemic and secreted antibody responses in murine models (39, 40) . BALB/c mice were subjected to immunization regimens of three single doses, with each dose containing 10 8 spores of the LDV702 or LDV704 strain, delivered via the sublingual or nasal route. Two weeks after the last dose, mice immunized were given orally to BALB/c mice (n ϭ 4). On days 1 (c) and 6 (d) postadministration, the animals were sacrificed. PPs were surgically removed, homogenized, and plated on LB supplemented with antibiotics for the determination of viable spores and vegetative cells. The assay was performed in duplicate and independently repeated at least three times. Values are expressed as means Ϯ SDs, and the results obtained by statistical analyses represent the differences between the tested strains and the LDV702 strain (*, P Ͻ 0.05; ***, P Ͻ 0.001).
by the sublingual route developed higher anti-P1 39-512 serum IgG levels than mice orally immunized with 9 doses (10 10 spores/dose) of spores of the same strains ( Fig. 4a and b) . Similar results were also observed in mice immunized with spores of the LDV702 and LDV704 strains via the nasal route. In addition, anti-P1 39-512 antibodies raised in immunized mice inhibited the binding of S. mutans to immobilized SAG, and this was particularly the case for those samples collected from mice immunized with LDV704 spores (Fig. 4d) . To evaluate the immunogenicity of the recombinant spores among genetically heterogeneous animals, we repeated the immunizations with Swiss mice. For this purpose, mice were immunized by the sublingual route with recombinant spores of the LDV704 and LDV702 strains. For this step, we used the sublingual immunization route because previous results from our group and others have demonstrated that this administration route is safe and particularly efficient for inducing antigen-specific IgG responses (42, 43, 45) . The results demonstrated that mice immunized with spores of the LDV704 and LDV702 strains developed high anti-P1 IgG responses (445 and 249 g/ml, respectively) (Fig. 4c) . In addition, anti-P1 antibodies raised in mice immunized with LDV704 spores inhibited the binding of S. mutans cells to immobilized SAG more efficiently (17% adherence inhibition) than antibodies raised in mice immunized with the LDV702 spores (3% adherence inhibition) (Fig. 4d) . Altogether, these results demonstrate that the recombinant B. subtilis spores also displayed good performance as antigen delivery vectors in a genetically heterogeneous mouse population.
DISCUSSION
Despite the attractive features of bacterial spores as live vaccine vectors, the low immunogenicity of passenger antigens observed after oral administration to mammalian hosts represents a challenge to be faced before B. subtilis spores can be considered a viable alternative as a mucosal delivery system. Our results demonstrate that engineered B. subtilis spores can persist longer within the mammalian gastrointestinal tract, interact with GALT afferent -specific serum samples. The inhibition of adherence was determined using the following formula: 100 Ϫ [(A 600 of NG8 cells incubated with the tested serum sample ϫ 100)/A 600 of NG8 cells not incubated with mouse serum]. All tested serum samples were obtained after the last dose and were used at the same concentration (2 g/ml of P1-specific IgG). The results represent the averages of three independent experiments performed in triplicate. Statistically significant differences compared with the results obtained with the B. subtilis LDV702 strain are indicated (*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001).
sites, and, more relevantly, improve the adjuvant effects of passenger antigens by the simple expression of bacterial adhesins at the spore surface. Expression of the binding region of the L. brevis S-layer protein (SlpA) and Y. pseudotuberculosis invasin (InvA) as gene fusions with a spore coat protein (CotB) enhanced serum and salivary antibody responses to P1 and increased the neutralizing effects of antibodies directed against S. mutans cells. Thus, the experimental evidence demonstrates that a single genetic manipulation step caused a drastic change in the behavior of B. subtilis spores and increased the perspectives for using spores as a platform for the mucosal delivery of heterologous antigens with diverse biotechnological applications.
Displaying adhesins capable of recognizing receptors expressed by gut epithelial cells not only increased the interaction of spores with GALT afferent sites but also enhanced the numbers of germination/sporulation cycles during transit through the murine gastrointestinal tract. The final numbers of spores and cells of the B. subtilis strains expressing surface-exposed adhesins were at least 3 orders of magnitude higher than those of the parental strain. Moreover, the spore/vegetative cell ratios measured with the recombinant strains were significantly lower than those detected with the parental strain (Table 1) , which might result in higher antigen loads expressed in vivo (9, 10) . This experimental evidence led us to propose a hypothetical model to explain the impact of SlpA expression and, particularly, InvA on the immunogenicity of antigens mucosally delivered by spores (Fig. 5) . Adhesin-expressing spores would interact more efficiently with M cells, likely leading to the transcytosis of a large number of spores that are ultimately captured by intraepithelial antigen-presenting cells, such as macrophages and dendritic cells (Fig. 5) . Once ingested by these phagocytic cells, as well as B cells, recombinant spores would germinate in phagosomes, where the activation of the gsiB promoter would drive antigen synthesis either to follow conventional processing and presentation pathways, leading to the activation of effector T and B cells, or as an antigen source for cross-presentation to intraepithelial B cells. As a final consequence, the local and The inhibition of the adherence was determined using the same formula presented in the legend to Fig. 3 . All tested serum samples were obtained after the last dose (pool) and were used at the same concentration (2 g/ml of P1-specific IgG). Immunization groups are indicated in the graph (x axis). The results represent the averages of three independent experiments performed in triplicate. Statistically significant differences compared with the results obtained with the B. subtilis LDV702 strain are indicated (*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001).
systemic production of antigen-specific antibody responses would be enhanced, as demonstrated by the augmented production of anti-P1 39-512 salivary IgA and serum IgG. Interestingly, previous attempts to employ a natural B. subtilis strain capable of persisting longer in the gut gastrointestinal tract of mice did not enhance the immunogenicity of a target antigen fused at the spore coat (43) . Therefore, it is possible to infer that specific spore targeting to GALT afferent sites, mediated by surface-exposed adhesins, and the expression of the vaccine antigen after spore germination represent key features involved in the higher immunogenicity of the recombinant B. subtilis spores.
To further evaluate the versatility of this spore-based mucosal antigen delivery method, we tested the performance of the adhesive spores using two alternative mucosal administration routes. Recombinant spores administered via the sublingual and nasal routes resulted in a dramatic enhancement in the immunogenicity of the passenger antigen, with high serum antibody responses being achieved even after a single vaccine dose containing 10 8 spores (a 100-fold smaller dose in comparison with that administered by the oral route). Such a performance regarding the induction of antigen-specific antibody responses is similar to that achieved with mucosa-delivered attenuated bacterial species, such as Salmonella. Indeed, the advantageous use of the sublingual route for the administration of B. subtilis spores has been emphasized previously (41, 42) . Our results also demonstrate that an enhanced immune response to a passenger antigen can also be achieved in a genetically heterogeneous mouse strain, further supporting the use of recombinant B. subtilis as a new platform for the delivery of antigens via mucosal routes.
Currently, two experimental approaches have been developed for the generation of B. subtilis spores as live vaccine vectors: one is based on the expression of the target antigen as a fusion protein at the spore coat (6-8, 13, 43) , whereas the second involves expression of the antigen after spore germination (9) (10) (11) . The present results represent the first demonstration of a combination of two antigen expression strategies: one active during spore formation, leading to the surface display of recombinant adhesins at the spore surface, and a second pathway leading to the intracellular expression of the target antigen shortly after spore germination. The combination of the two heterologous protein expression systems significantly enhanced the immunogenicity of antigens delivered by B. subtilis spores following administration via mucosal routes. The discovery that the immunological performance of B. subtilis spores as antigen delivery vectors can be significantly improved by expressing bacterial adhesins, particularly InvA, on the spore surface therefore represents the basis of a second-generation sporebased antigen delivery system endowed with enhanced adjuvant effects and compatible with administration via different mucosal routes. In addition, the S. mutans neutralization effects achieved with the presently reported antigen expression strategy open new and promising avenues for the development of anticaries vaccines.
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